| 1 |
30296044 | [C-REACTIVE PROTEIN AS AN INDICATOR OF RISK OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ITS CORRECTION]. | 2016 |
2 |
| 2 |
23166441 | Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. | 2012 |
1 |
| 3 |
20841306 | Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations. | 2011 Mar-Apr |
4 |
| 4 |
21645507 | Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. | 2011 Sep |
1 |
| 5 |
19146796 | The role of incretins in cardiovascular control. | 2009 Feb |
1 |
| 6 |
19383034 | Exenatide: a review from pharmacology to clinical practice. | 2009 Jun |
1 |
| 7 |
18366986 | Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. | 2008 Feb |
1 |
| 8 |
17872344 | Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. | 2007 Sep |
1 |